Regenxbio Inc (NAS:RGNX)
$ 11.6 -0.51 (-4.21%) Market Cap: 573.31 Mil Enterprise Value: 393.69 Mil PE Ratio: 0 PB Ratio: 1.64 GF Score: 69/100

Q1 2022 Regenxbio Inc Earnings Call Transcript

May 04, 2022 / 08:30PM GMT
Release Date Price: $28.44 (+0.78%)
Operator

Good day, and thank you for standing by. Welcome to the Q1 2022 REGENXBIO Inc. Earnings Conference Call. (Operator Instructions)

I would now like to hand the conference over to our speaker today, Mr. Patrick Christmas, Chief Legal Officer. Please go ahead.

Patrick J. Christmas
REGENXBIO Inc. - Executive VP & Chief Legal Officer

Good afternoon, and thank you for joining us today. With us are Ken Mills, REGENXBIO's President and Chief Executive Officer; Dr. Steve Pakola, our Chief Medical Officer; and Vit Vasista, our Chief Financial Officer. Earlier this afternoon, REGENXBIO released financial and operating results for the first quarter ended March 31st, 2022. The press release reporting our financial results is available on our website at www.regenxbio.com.

Today's conference call will include forward-looking statements regarding our financial outlook in addition to regulatory and product development plans. These forward-looking statements are subject to risks and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot